SCHEMBL12337291

SCHEMBL12337291

CCN1CC(NC)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14440031 0.90
SCHEMBL15079109 0.80
SCHEMBL2549878 0.80
SCHEMBL13832821 0.80
SCHEMBL24788162 0.80
SCHEMBL29332856 0.80 HRH2 (0.31)
SCHEMBL19871788 0.79
Hydrochloric Acid SCHEMBL13739081 0.79 HRH3 (0.40)
Hydrochloric Acid SCHEMBL13738417 0.79 HRH3 (0.40)
Hydrochloric Acid SCHEMBL13738414 0.79 HRH3 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117263839-A Synthesis method of substituted nitrogen heterocyclic compound 苏州爱玛特生物科技有限公司 2023-12-22 CN disclosed
US-11787800-B2 BRD9 degraders and uses thereof FOGHORN THERAPEUTICS INC. (US) 2023-10-17 US disclosed
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 US disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed
WO-2022192598-A1 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2022-09-15 WO disclosed
US-20220048906-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2022-02-17 US disclosed
WO-2021126693-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-06-24 WO disclosed
WO-2020252015-A1 IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF SUTRO BIOPHARMA, INC. (US) 2020-12-17 WO disclosed
WO-2020252043-A1 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF SUTRO BIOPHARMA, INC. (US) 2020-12-17 WO disclosed
WO-2020198526-A2 SMALL MOLECULE MODULATORS OF PANK ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2020-10-01 WO disclosed
US-20190248767-A1 Tetrahydroquinazoline Derivatives Useful as Anticancer Agents PFIZER INC. (US) 2019-08-15 US disclosed
US-20190209574-A1 SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS ARRIEN PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-3041841-B1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2019-06-05 EP disclosed
WO-2017189829-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF SAMUMED, LLC (US) 2017-11-02 WO disclosed
US-9783524-B2 Protein tyrosine kinase modulators and methods of use BETTA PHARMACEUTICALS CO., LTD. (CN) 2017-10-10 US disclosed
US-20160145237-A1 PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE BETTA PHARMACEUTICALS CO., LTD (CN) 2016-05-26 US disclosed
CN-103764641-A Partially saturated tricyclic compounds and methods of making and using same ZAFGEN CORP 2014-04-30 CN disclosed
US-8399681-B2 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2013-03-19 US disclosed
US-20120302544-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS BIGNAN GILLES (US) 2012-11-29 US disclosed
US-8263781-B2 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 US disclosed